SCHEMBL24316561

SCHEMBL24316561

COc1cc(N2CCCc3ccc(C#N)cc32)c2cc(C)c(=O)n(C)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRPF1 P55201 9/20 0.40
▸ BRD1 O95696 6/20 0.40
▸ BRPF3 Q9ULD4 6/20 0.40
▸ BRD4 O60885 4/20 0.40
▸ BRD9 Q9H8M2 4/20 0.40
▸ BRD7 Q9NPI1 2/20 0.39
▸ TRIM24 O15164 1/20 0.39
▸ TUBB4A P04350 3/20 0.37
▸ TUBB P07437 3/20 0.37
▸ TUBA3C P0DPH7 3/20 0.37
▸ TUBA1B P68363 3/20 0.37
▸ TUBA4A P68366 3/20 0.37
▸ TUBB4B P68371 3/20 0.37
▸ TUBB3 Q13509 3/20 0.37
▸ TUBB2A Q13885 3/20 0.37
▸ TUBB8 Q3ZCM7 3/20 0.37
▸ TUBA3E Q6PEY2 3/20 0.37
▸ TUBA1A Q71U36 3/20 0.37
▸ TUBA1C Q9BQE3 3/20 0.37
▸ TUBB6 Q9BUF5 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26548842 0.86 BRPF1 (0.41) BRPF1BRD4BRD9TUBB4ATUBB
SCHEMBL29471259 0.84 BRPF1 (0.39) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL26548588 0.84 BRPF1 (0.39) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL26547524 0.84 TUBB4A (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24316820 0.83 CREBBP (0.36) BRD4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29471207 0.82 ROCK1 (0.36) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29471266 0.82 CA1 (0.41) BRPF1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31542282 0.82 BRPF1 (0.37) BRPF1BRD1BRPF3BRD4BRD9
SCHEMBL29471205 0.82 TP53 (0.38) BRPF1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL26548859 0.82 TP53 (0.38) BRPF1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
WO-2022053967-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 BRPF1 216/4885BRD1 15/4885BRPF3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback